European Journal of Radiology
Volume 45, Issue 1 , Pages 31-38 , January 2003

Extra-thoracic staging of lung cancer

Received 17 September 2002 ,Revised 18 September 2002 ,Accepted 19 September 2002.

References 

  1. Kadri MA, Dussek JE. Survival and prognosis following resection of primary non small cell bronchogenic carcinoma. Eur. J. Cardiothoracic Surg. 1991;5(3):132–136
  2. Quint LE, Francis IR. Radiologic staging of lung cancer. J. Thorac. Imaging. 1999;14(4):235–246
  3. Ichinose Y, Hara N, et al.  Preoperative examination to detect distant metastasis is not advocated for asymptomatic patients with stages 1 and 2 Non-Small Cell Lung Cancer. Chest. 1989;96(5):1104–1109
  4. Hatter J, Kohman LJ, Mosca RS, et al.  Preoperative evaluation of stage I and stage II non-small cell lung cancer. Ann. Thorac. Surg. 1994;58(6):1738–1741
  5. Ferrigno D, Buccheri G. Cranial computed tomography as a part of the initial staging procedure for patients with non-small-cell lung cancer. Chest. 1994;106(4):1025–1029
  6. The Canadian Lung Oncology Group . Investigating extrathoracic metastastic disease in patients with apparently operable lung cancer. Ann. Thorac. Surg. 2001;71:425–434
  7. Mintz BJ, Tuhrim S, Alexander S, Yang WC, Shanzers S. Intracranial metastases in the staging of bronchogenic carcinoma. Chest. 1984;86:850–853
  8. Yokoi K, Kamiya N, Matsuguma H, et al.  Detection of brain metastases in potentially operable non-small cell lung cancer. A comparison of CT and MRI. Chest. 1999;115(3):714–719
  9. Patchell RA, Tibbs PA, Walsh JW, et al.  A randomised trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 1990;322(8):494–500
  10. Sze G, Shin J, et al.  Intraparenchymal brain metastases: MR imaging versus contrast-enhanced CT. Radiology. 1998;168(1):187–194
  11. Marom EM, McAdams HP, Erasmus JJ, et al.  Staging non-small cell lung cancer with whole body PET. Radiology. 1999;212:803–809
  12. Glazer HS, Weyman PJ, Sagel SS, et al.  Non functioning adrenal masses: incidental discovery on computed topography. Am. J. Roentgenol. 1982;139:81–85
  13. Pagani JJ. Normal adrenal glands in small cell lung carcinoma: CT-guided biopsy. Am. J. Roentgenol. 1983;140(5):949–951
  14. Oliver TW, Bernadino ME, Miller JL, et al.  Isolated adrenal masses in non-small-cell bronchogenic carcinoma. Radiology. 1984;153:217–218
  15. Ekholm S, Albrechtsson U, Kugelberg J, Tylen U. Computed topography in preoperative staging of bronchogenic carcinoma. J. Comput. Assist. Tomogr. 1980;4(6):763–765
  16. Hirleman MT, Yiu-Chiu VS, Chiu LC, Schapiro RL. The resectability of primary lung carcinoma: a diagnostic staging review. J. Comput. Tomogr. 1980;4(2):146–163
  17. Gillams A, Roberts CM, Shaw P, Spiro SG, Goldstraw P. The value of CT scanning and percutaneous fine needle aspiration of adrenal masses in biopsy-proven lung cancer. Clin. Radiol. 1992;46(1):18–22
  18. Bernadino ME, Walther MM, Philips VM, et al.  CT guided adrenal biopsy: accuracy, safety, and indications. Am. J. Roentgenol. 1985;144:66–69
  19. Boland GWL, Lee MJ, Scott Gazelle G, et al.  Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. Am. J. Roentgenol. 1998;171:201–204
  20. Boland GW, Hahn PF, Pena C, et al.  Adrenal masses: characterization with delayed contrast-enhanced CT. Radiology. 1997;202:693–696
  21. Korobkin M, Brodeur FJ, Francis IR, et al.  Delayed enhanced CT for differentiation of benign from malignant adrenal masses. Radiology. 1996;200(3):737–742
  22. Boland GW, Hahn PF, Pena C, Mueller PR. Adrenal masses: characterization with delayed contrast-enhanced CT. Radiology. 1997;202(3):693–696
  23. Chezmar JL, Robin SM, Nelson RC, et al.  Adrenal masses: characterization with T1 weighted imaging. Radiology. 1998;166:357–359
  24. Krestin GP, Stenbrick W, Friedman G. Adrenal masses; evaluation with fast echo MR imaging and Gd-DTPA enhanced dynamic studies. Radiology. 1989;171:675–680
  25. Korobkin M, Lombardi TJ, Aisen AM, et al.  Characterization of adrenal masses with chemical shift and gadolinium-enhanced MR Imaging. Radiology. 1995;197:411–418
  26. Pender SM, Boland GW, Lee MJ. The incidental non-hyperfunctioning adrenal mass: an imaging algorithm for characterization. Clin. Radiol. 1998;53(11):796–804
  27. Erasmus JJ, Patz EF, Page McAdams H, et al.  Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxy-glucose positron emission topography. Am. J. Roentgenol. 1997;168:1357–1360
  28. Silverman PM, O'Malley J, et al.  Conspicuity of hepatic metastases on helical CT: effect of different time delays between contrast administration and scanning. Am. J. Roentgenol. 1995;164:619–623
  29. Patz EF, Erasmus JJ, et al.  Lung cancer staging and management: comparison of contrast-enhanced and nonenhanced helical CT of the thorax. Radiology. 1999;212:56–60
  30. Jones EC, Chezmar JL, Nelson RC, Bernadino ME. The frequency and significance of small (less than or equal to 15 mm) hepatic lesions detected by CT. Am. J. Roentgenol. 1992;158(3):535–539
  31. Ward J, Naik KS, Guthrie JA, et al.  Hepatic lesion detection: comparison of MR imaging after the administration of super paramagnetic iron oxide with dual phase CT. Radiology. 1999;210:459–466
  32. Ito K, Mitchell DG, Outwater EK, et al.  Hepatic lesions: discrimination of non solid benign lesions from solid malignant lesions with heavily T2 weighted fast spin-echo MR Imaging. Radiology. 1997;204:729–737
  33. Mitchell DG, Kim I, Chang TS, et al.  Chemical shift phase difference and suppression magnetic resonance imaging techniques in animals, phantoms, and humans. Invest. Radiol. 1991;26:1041–1052
  34. Blomley MH, Allbrecht T, Cosgrove DO, Patel N, et al.  Improved imaging of liver metastases with stimulated acoustic emission in the late phase of enhancement with the US contrast agent SH U 508A—early experience. Radiology. 1999;210:409–416
  35. Harvey CJ, Blomley MJK, et al.  Developments in ultrasound contrast media. Eur. Radiol. 2001;11:675–689
  36. Donato AT, Ammerman EG, Sullesta O. Bone scanning in the evaluation of patients with lung cancer. Ann. Thorac. Surg. 1979;27(4):300–304
  37. Lewis P, Griffin S, et al.  Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet. 1994;344(8932):1265–1266
  38. Weder W, Schmid RA, Bruckhaus H, et al.  Detection of extra-thoracic metastases by positron emission topography in lung cancer. Ann. Thorac. Surg. 1998;66:886–893
  39. Valk PE, Pounds TR, et al.  Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann. Thorac. Surg. 1995;60:1573–1582
  40. Van Tinteren H, Hekstra OS, Smit EF, et al.  Effectiveness of positron emission tomography in the preoperative assesment of patients with suspected non small-cell lung cancer: the PLUS multicentred randomised trial. Lancet. 2002;359:1388–1393

PII: S0720-048X(02)00299-1

European Journal of Radiology
Volume 45, Issue 1 , Pages 31-38 , January 2003

Article Tools

* Image Usage & Resolution